Stem Cell Clinic

Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

By Global News Feed

DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.

Read more:
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

By Global News Feed

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has completed the last subject visit in its Phase 1 clinical trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan). This achievement has triggered a milestone payment to aTyr.

See the original post:
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium

By Global News Feed

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that its President Sam Lee, Ph.D. will be making a presentation at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine, being held January 21, 2021.

Read more from the original source:
Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium

Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

By Global News Feed

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.

Read more here:
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

By Global News Feed

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

Read the original here:
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews

By Global News Feed

Fuel4Thought™ proprietary formulation pilot study reduced the number of Migraine episodes by 39% and the average duration by 61% Fuel4Thought™ proprietary formulation pilot study reduced the number of Migraine episodes by 39% and the average duration by 61%

More here:
Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews

PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology

By Global News Feed

Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment

Go here to see the original:
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology

Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in…

By Global News Feed

DAVIS, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (NASDAQ: MBII) (MBI), a global provider of bio-based crop protection and plant health products, today announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA).

The rest is here:
Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in...

→←